Oral · GLP-1 agonist
MDR-001
6 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
6
Active
6
Recruiting
1
Completed
0
Sites
57
Countries
1
Endpoints
78
Composite endpoints
2
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
3
Phase 1/2
1
Phase 2
1
Phase 3
1
Trials by status
Not yet recruiting
5
Recruiting
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
36
Weight & body composition
20
Cardiometabolic biomarkers
14
Glycemic / diabetes
6
Other (unclassified)
2
Most-measured metrics
Top 20 metrics across this asset's endpoints
CmaxSafety/PK
2
AUC₀–∞Safety/PK
2
TmaxSafety/PK
2
Half-lifeSafety/PK
2
Heart rate, changeBiomarker
2
Treatment-emergent AEs (any)Safety/PK
1
Thyroid eventSafety/PK
1
Systolic BP, changeBiomarker
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
6 of 6